Ascletis Pharma Inc./歌礼生物科技（杭州)有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study 2020-12-04 08:00
Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer 2020-11-30 08:00
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China 2020-11-19 08:30
Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH 2020-11-18 17:00
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist 2020-10-12 08:30
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist 2020-10-12 08:30
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist 2020-09-14 08:30
Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist) 2020-09-09 18:30
Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen 2020-08-20 20:00
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody 2020-08-17 08:30
Ascletis' All-oral HCV Treatment Approved for Marketing in China 2020-07-31 08:47
Bridging Study in China Completed for NASH Drug Candidate ASC40 2020-07-20 08:30
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial 2020-06-17 20:30
Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication 2020-05-13 18:30
Ascletis Receives IND Approval for its HIV Drug ASC09F 2020-04-13 20:00
Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020 2020-04-01 08:30
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients 2020-03-25 08:28
Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia 2020-03-10 17:30
Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia 2020-02-27 08:00
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA 2020-02-18 08:00
1 5 6 7 8 9